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ABSTRACT 
 
The development of new strategies based on cell therapy approaches to correct 
haemophilia A (HA) requires further insights into new cell populations capable of 
producing coagulation factor VIII (FVIII) and presenting stable engraftment 
potential. The major producers of FVIII in the adult are liver sinusoidal endothelial 
cells (LSEC) and in a lesser degree bone marrow (BM)-derived cells, both of which 
have been shown to ameliorate the bleeding phenotype in adult HA mice after 
transplantation. We have previously shown that cells from the foetal liver (FL) and 
the aorta-gonads-mesonephros (AGM) hematopoietic locations possess higher 
LSEC engraftment potential in new-born mice compared to adult-derived LSECs, 
constituting likely therapeutic targets for the treatment of HA in neonates. 
However less is know about the production of FVIII in embryonic locations. Q-PCR 
and Western blot analysis were performed to assess the relative level of FVIII 
production in different embryonic tissues and at various developmental stages, 
identifying the FL and AGM region from day 12 (E12) as prominent sources of 
FVIII.  Furthermore, FL-derived VE-cad+CD45-Lyve1+/- endothelial/endothelial 
progenitor cells, presenting vascular engraftment potential, produced high levels 
of F8 ribonucleic acid compared to CD45+ blood progenitors or Dlk1+ 
hepatoblasts. In addition, we show that the E11 AGM explant cultures expanded 
cells with LSEC repopulation activity, instrumental to further understand signals 
for in vitro generation of LSECs. Taking into account the capacity for FVIII 
expression, culture expansion and new-born engraftment potential, these results 
support the use of cells with foetal characteristics for correction of FVIII deficiency 
in young individuals.  
 
Key words: foetal liver, AGM, Factor VIII, Haemophilia therapy, new-born 
transplantation, LSEC. 
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INTRODUCTION 
Haemophilia A (HA), with an incidence of one in every 5000-10,000 males 
worldwide (1, 2), is a well-known hereditary bleeding disorder. The condition is 
caused by different mutations in the X-linked F8 gene that encodes for the 
coagulation factor VIII (FVIII). F8 genetic alterations result in deficient production 
or dysfunction of FVIII. Current therapies involve administration of plasma 
derived FVIII or synthetic recombinant products. Although successful, protein 
replacement therapy constitutes a life-long treatment rather than a cure for the 
disease. Furthermore, the treatment can induce the production of neutralizing 
antibodies or “inhibitors” and as a consequence, patients can no longer use FVIII 
concentrates. Development of inhibitors can also be life threatening for high-risk 
patients such as infants and compromised individuals (3, 4). Therefore, it would 
be important to research into safer and viable cell-based therapies directed 
specially towards the treatment of the younger patients. One essential element in 
a cell-based therapy approach is the cell source used. Once the optimal cell type is 
established, iPS cell-derived protocols can potentially be tailored to obtain 
suitable cell types for transplantation from valid and reliable sources. Studies 
using cell therapy approaches (5) or cell lineage specific knockout mice (6, 7), have 
shown that secretion of endothelial-cell derived FVIII is essential for the 
coagulation-cascade to operate. The liver sinusoidal endothelial cells (LSEC), 
identified by markers such us the hyaluronan receptor-1 (Lyve1) (8), represent 
one of the principal producers of FVIII (9). Also hematopoietic cells from the adult 
can synthesize and secrete FVIII (10).  
To harness novel cell subsets for HA therapeutic purposes it is crucial that 
transplanted cells have the capability of stably and extensively engraft endothelial 
and hematopoietic cells, which are the relevant producers of FVIII at therapeutic 
levels in experimental transplantation settings.  The foetal liver (FL) and the aorta-
gonads-mesonephros (AGM) region of the embryo contain both hematopoietic 
and endothelial engraftment activities (11-13). During embryonic life 
hematopoietic development is closely intertwined with that of the vascular 
system. Blood cells and endothelium emerge in close proximity at stage E7 of 
mouse development leading to the proposal for the existence of a common 
haemangioblast progenitor (14). Transplantation assays into adult irradiated 
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hosts have shown that long-term multi-lineage engrafting hematopoietic stem 
cells (HSCs) emerge in the dorsal aorta (DA) of the AGM region at E10.5 (15). By 
E12, both the AGM and FL cells have hematopoietic and multi organ vascular 
engraftment potential, including liver sinusoidal engraftment, with FL cells 
contributing prominently to the vasculature (12, 13, 16).  Further characterization 
of E12 FL cell populations has shown that cells expressing the hemato/vascular 
transgenic reporter vector SCL-PLAP (17) contain both HSCs (VE-cad+/-CD45+) 
and cells with long-term reconstituting endothelial cell (LTR-EC) capabilities, 
including LSEC engraftment potential (VE-cad+CD45-Lyve1+/- cells) (13). 
Importantly, these VE-cad+CD45-Lyve1+/- cells present higher vascular 
reconstitution capacity than their adult derived LSEC counterpart cells (13, 18). 
In general FL derived cells seem to posses stronger repopulation activity 
compared to adult-derived progenitors, including HSCs (19, 20) and parenchymal 
progenitor cells (21), thus constituting a potential target for cell therapeutic 
approaches. 
Vascular and hematopoietic engraftment efficiency varies depending on the 
transplantation models and preconditioning regimes of the host. Vascular 
integration of transplanted adult LSECs requires extreme damage conditioning 
treatments of unrealistic translational values to individuals with HA, including 
hepatectomy, the use of highly toxic agents, irradiation or severe genetic 
predisposition (22-24). We have shown that FL cells can engraft blood and LSECs 
when transplanted into in busulfan treated new-born mice, a precondition regime 
that seems to be less damaging (25). Therefore transplantation of fetal cells into 
HA new-borns may be a suitable approach for HA treatment at early age.  
While FVIII production has been well characterized in adult LSEC and blood cells 
(9, 10), very little effort has been applied to the identification of FVIII-producing 
locations in the developing embryo. Here we describe an extensive analysis of F8 
transcript production in different embryonic/foetal tissues during development, 
identifying a predominant window of F8 RNA expression at E12 in AGM cells and 
FL derived VE-cad+CD45-Lyve1+ and VE-cad+CD45-Lyve1- cell populations. In 
addition, it was shown that cultures of AGM explants can expand cells with LSEC 
engraftment potential, providing a framework to further analyse molecular 
mechanisms involved in the emergence/expansion of cells with LSEC potential. 
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The data presented constitute the basis for further selection of novel foetal cell 
types with endothelial/hematopoietic engraftment potential in new-born 
recipient mice, which could be instrumental for early age correction of the 
bleeding phenotype in HA individuals. 
 
MATERIAL AND METHODS 
Mice and embryo generation 
Mice were bred and housed at CABD MF and maintained in a mixed (CBA × 
C57BL/6) background. Wild type and SCL-PLAP transgenic mice (17) were used.   
To obtain embryonic/foetal tissue matings were set up and the day of vaginal plug 
detection was designated as embryonic day 0. Embryos were obtained from day 8 
(E8) to day 12 (E12) of gestation. Cell preparation procedures from 
embryonic/foetal and adult hematopoietic tissues were previously published (13, 
26). All animal procedures were approved by the Universidad Pablo de Olavide 
Ethical Review Board and performed in compliance with Standards for Care and 
Use of Laboratory Animals following the European Union legislation. 
 
RNA isolation and qRT-PCR for F8 
For qRT-PCR, total RNA was extracted using NZY total RNA isolation kit (NZYtech, 
Ltd) and quantitated by a NanoDrop One (ThermoFisher Scientific, 
Massachusetts). cDNA was generated using High-Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems, CA, USA), from 1 μg of RNA as starting 
material. Quantitative real-time polymerase chain reaction (qRT-PCR) was 
performed using GoTaq® qPCR Master Mix (Promega, Wisconsin, USA), samples 
run on Thermal Cycler (7500 fast Real-Time PCR System, Applied Biosystems, CA, 
USA) on the stages: Holding stage to 50ºC 2’ and 95ºC 10’, Cycling Stage 40 cycles 
to 95ºC 15’’ and 60ºC 1’ and Melt curve Stage to 95ºC 15’’, 60ºC 1’, 95ºC 30’’ and 
60ºC 15’’ and analysed using relative expression genes method (2-ΔCt), Ct- values 
were processed and normalized to GAPDH to account for total amount of RNA in 
each individual sample. Samples contained tissues from at least two different 
embryos and were run in triplicates. Each biological replica was obtained from 
individual pregnant females. The PCR primers designed for mouse F8 and GAPDH 
genes are shown in Table 1.  
 6 
 
Western Blot 
FVIII production was analysed by Western blotting. In brief, samples obtained 
from E12 embryo tissues, adult liver and 1x106 HepG2 cell line were frozen, 
resuspended in SDS buffer (100 mM TrisHCl pH 6.8, 4% SDS, 20% glycerol)  with 
protease inhibitor cocktail (Roche Applied Bioscience) and lysed by sonication at 
10% amplitude with 10 pulses of 10 sec on/10 sec off. After sonication, samples 
were centrifuged at 16.000g for 20 min at 4ºC and supernatants were collected. 
Protein concentrations were measured using the RC/DC Protein Assay kit 
(BioRad). Total protein extract from embryonic tissues, HepG2 cell lysate and 
adult liver were loaded in 7.5% TGX Stain-FreeTM FastCastTM Acrylamide (BioRad) 
gel under reducing conditions and blotted onto Nitrocellulose membranes. The 
Precision Plus Protein Standard All Blue (BioRad) was run in the same gel. 
Western Blot normalization was performed using total protein load following 
manufacturer protocol for Stain Free gels kit (Bio Rad).  FVIII monoclonal 
antibody (R8B12) (sc-73597) that recognises the A2 domain of the human and 
mouse FVIII heavy chain, used at 1:250 dilution and the (RFFVIII C/5)  (sc-59512) 
that recognises de FVIII light chain, used at 1:400 were employed as primary 
antibodies , followed by incubation with m-IgGĸ BP-HRP secondary antibody 
(Santa Cruz Biotechnology, sc-516102) diluted to 1:2000.  Chemiluminiscent 
signals were detected with ECL Prime reagent (GE Healthcare) in a ChemiDoc XRS 
Imaging System (BioRad). Cell lysates from human HepG2 hepatocellular 
carcinoma cell line were kindly provided by Dr JA Sanchez Alcazar, CABD, Seville. 
 
Cell analysis and sorting by flow cytometry 
Cell suspensions were stained, analysed and separated by flow cytometry as 
previously described (13). A FACSAria flow cytometer equipped with two lasers 
and run with a FACSDiva software (BD Biosciences, www.bdbiosciences.com/eu) 
was used. 
 
AGM and FL explant cultures 
AGM and FL were dissected form E11 embryos and cultured in explants for 3 days 
as previously described (11, 15, 27). Briefly, AGMs and FL were removed in D-PBS 
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Ca+Mg+ (Sigma‐Aldrich, USA), deposited on 0.65 m nylon filters (DVPP02500 
Millipore, USA) placed on metallic supports immersed in 6 well plates containing 
5 ml myeloid long-term culture medium (M5300 Stem Cell Technologies, Canada) 
supplemented with 10μM hydrocortisone (H2270 Sigma, Germany) in an air-
liquid interphase. For cell suspension, FL and FLex were mechanically 
homogenate. Uncultured AGM and AGM explanted tissues were incubated in 
0.12% collagenase type XI (Sigma-Aldrich, USA) in D-PBS (Sigma‐Aldrich, USA) 
supplemented with 5% FCS (GE Helthcare, HyClone, USA) and 100U/ml penicillin, 
100μg/ml streptomycin (1%P/S) (GE Helthcare, HyClone, USA) at 37ºC for 30 
min, further dissociated by pipetting and centrifuged in D-PBS 10% FSC.  For 
transplantation cells were re-suspended in D-PBS 1%FCS 1%P/S.  
 
Transplantation into busulfan treated new-born mice and hematopoietic 
and vascular chimerism determination  
Uncultured and explanted AGM and FL cell suspension obtained from SCL-PLAP 
transgenic embryos, were injected intravenously (i.v.) into busulfan conditioned 
2 days old wild type new-born mice following previously published protocols (13, 
28). For details of AGM and FL embryo equivalents/cell numbers injected and the 
number of experiments performed see Table 2. After 4 months mice were 
anesthetized, blood collected from the heart and perfused with 50 ml Tris- 
buffered saline containing 0.001% heparin.  For determination of hematopoietic 
chimerism, blood samples were depleted of erythroid cells (12), stained for CD45 
and PLAP and analysed by flow cytometry for quantification of the donor-derived 
reporter gene PLAP. The SCL-PLAP reporter vector is only expressed in a 
proportion of circulating cells in transgenic mice detected by FACS analysis 
(15±5%). A correlation between the level of chimerism in peripheral blood 
determined by FACS-PLAP and semi-quantitative PCR-PLAP for genomic DNA was 
previously established, showing that values ≥5% by FACS-PLAP correspond to 10-
100% total hematopoietic chimerism determined by semi-quantitative PCR-PLAP 
(12, 13).  Host animals presenting >1% of PLAP+ cells by flow cytometry in 
circulation were considered as hematopoietic chimeras (equivalent to 
approximately 5% of total donor chimerism). PCR-PLAP on genomic DNA was 
used to determine the presence of donor-derived cells in mice from which blood 
 8 
samples were not available for FACS analysis (see Table 2). For vascular 
engraftment valuation, the liver was removed, fixed in zinc solution (BD-
Pharmingen CA, USA) and wax embedded. Nitroblue tetrazolium (NBT) staining 
on host liver sections was performed to detect the donor-derived human alkaline 
phosphatase (SCL-PLAP) transgene expression. Systematic histological screening 
for SCL-PLAP+ donor-derived sinusoidal vascular-like clusters (v.c.) on liver 
sections was performed as previously published (12, 13). For quantification of 
vascular engraftment on NBT stained liver sections the frequency of mice positive 
for v.c. and the relative tissue area containing v.c., denominated vascular cluster 
area (v.c.a.), were determined using the Image AnalySIS software program 
V3.1.110 as published (13).  
 
Histological staining 
Triple immune-staining for reporter gene hPLAP, pan-leukocyte marker CD45 and 
endothelial marker Isolectin B4 (IsoB4) was performed on paraffin liver sections 
to confirm the endothelial nature of the v.c. as described (12). DAPI staining was 
used to identify the nuclei.  Images were taken with a Leica SP2 confocal 
microscope.  
 
Statistical analysis  
Data are expressed as mean ±SD. Relation of F8 RNA level production and 
age within whole embryos and tissues was assessed by means of regression 
analysis taking the logarithm of the 2-ΔCt values as dependent variable and the 
stage as independent variable.  To evaluate if there were differences in the 
expression of F8 RNA at stage E12 between the different tissues a U-Mann–
Whitney test was carried out. The Statgraphics Centurion XVII software (Statpoint 
Technologies, Inc. USA) was used.  
 
RESULTS 
 
FVIII expression during mouse embryo development  
Total RNA was obtained from whole embryos and the relative levels of F8 
transcripts determined by qPCR using GAPDH as normalization control. This 
analysis showed consistent increment on the F8 RNA expression levels from E8 to 
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E12 stages (Figure 1A, Sup Table 1). To assess the spatio-temporal expression of 
F8 in specific embryonic/foetal locations, hematopoietic sites previously 
described to contain endothelial progenitors/endothelial cells were analysed, 
including the FL, AGM region and yolk sac (YS) (13, 14). From E10 to E12 very 
little variation in F8 RNA production levels occurred in the YS or FL compared 
with the progressive increase observed in the AGM region, with values in E12 AGM 
approximately 8 times higher than liver and yolk sac (Figure 1B).   As FVIII 
production has been detected in different types of endothelium from the adult 
individuals (9), the level of F8 RNA expression was also analysed from embryonic 
regions with less prominent or negative hematopoietic activity including the 
heart, head, dorsal-intermedial somites and limbs. In all tissues analysed it was 
observed a progressive increase of F8 RNA expression from E9 to E12 embryonic 
stages, superior to the production of F8 by the FL (Figure 1B).  Statistical 
regression analysis indicated a significant (p<0.05) correlation of age and 
increment on F8 RNA production in most samples, except for the yolk sac (YS) 
(Sup. Table 1). This might be associated with an increment of vasculogenesis 
associated to organogenesis, emphasized from E10-E11 (29, 30). Still the E12 
AGM region presented significant higher levels for F8 transcripts than any other 
tissue analysed.  
To assess FVIII protein production, we performed Western blot analysis with E12-
derived tissue lysates using adult liver andHepG2 cells line as positive controls. 
FVIII is synthesized as an approximately 300 kDa full-length protein consisting of 
A1-A2-B-A3-C1-C2 structural domains. The native protein is processed intra-
cellularly into a heterodimer comprising a heavy chain (HC), including the A1-A2-
B domains, with a molecular weight ranging from90 to 200 kDa depending on the 
length of the B domain, and a light chain (LC) of 80 kDa (A3-C1-C2 domains) (31-
33) . Using an anti-FVIII monoclonal antibody that recognizes an epitope in the A2 
domain, we detected different bands with a size corresponding to the unprocessed 
full-length protein, different processed HC fragments and an approximately 37 
kDa band, likely corresponding to the A2 domain  (34) (Figure 1D). The 
approximately 300 kDa band was detected in most foetal tissue samples, except 
for the YS (Figure 1D, i). Although we detected different processed fragments,we 
could not detect the full-length protein in the HepG2 or adult liver positive 
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controls, even after incrementing the amount of protein loading for adult liver 
(Figure 1D, ii). This may suggest a difference in FVIII processing between adult 
liver, the tumour cell line and cells of foetal origin. HC bands were present in most 
tissue samples, including the approximately 200 kDa peptide, likely 
corresponding to the A1-A2-B fragment, and a double band at approximately 100 
kDa comprising the 90-kDa fragment (A1-A2). The 90-kDa band was faint in foetal 
tissues and prominent in the adult liver (Figure 1D). The only exception was the 
YS where HC proteins were absent, in accordance with the low levels for F8 RNA 
expression. We also detected a low molecular weight band of approximately 37 
kDa in foetal tissues that was absent in the adult liver (Figure 1D). The 37- kDa 
band is present in the positive control HepG2 human cell line, reported to produce 
low levels of functional FVIII, (35, 36), supporting the idea that this fragment likely 
correspond to the A2 domain (Figure 1D). Classically, the A2 product is generated 
during thrombin-catalysed cleavage or proteolytic degradation, (31) hence we can 
only speculate that the detection in our samples might be due to its accumulation 
as a product of fast cytoplasmic processing of non-secreted FVIII, particularly 
accentuatedinHepG2,where almost noother bandisdetected. Most FVIIImight 
besecretedin the adult liver andconsequently no A2 product is detected. 
Mechanisms controlling intracellular FVIII proteolytic cleavage and fragment 
dissociation have been described in transfected cell lines, although it is not 
completely clear if similar mechanism apply to tissue-derived cells. (37, 38) To 
discard background cross-reactivity bands, we also performed membrane stained 
with only the secondary antibody. The only product detectedwas the 
approximately 60 kDa band (not shown), indicating that the A2 fragment is not 
unspecific. Overall, the presence of properly cleaved HC fragments suggests that 
the correct synthesis and processing of FVIII is occurring in E12 tissues. 
To further corroborate the processing of FVIII protein in foetal tissues, we also 
tested an anti-FVIII monoclonal antibody that recognizes the LC. Although the full-
length protein was only detected in the foetal head and somites, all samples 
presented the approximately 80-kDa band corresponding to the LC fragment, 
except for the YS and HepG2 (Supplementary Fig. S2, available in the online 
version). We cannot discard that the absence of the full-length band in some 
samples might be due to the lack of reactivity of the LC antibody related to the 
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characteristic of the tissues. More work will be needed to determine the precise 
cell types and the operating mechanisms for the synthesis, storage and secretion 
of FVIII and its correlation with the presence of different fragment sizes and band 
intensity in Western blot analysis. 
 
F8 RNA production in different cell populations from E12 FL 
The liver has been considered for a long time as the primary site of FVIII 
production since canine or human liver transplantation corrected HA (39, 40). 
Further work showed that liver LSEC are the main cellular source of hepatic FVIII 
(6, 7, 9). Cell-types other than endothelial cells with the capacity to synthesize and 
release FVIII have been identified in hepatic and extra hepatic locations in the 
adult, including hepatocytes, monocytes, macrophages, megakaryocytes and 
mesenchymal stromal cells (10). We have characterized a Ve-cad+CD45-Lyve1+/- 
cell population from the E12 FL with multi-organ vascular engraftment potential 
and a prominent contribution to the liver endothelial sinusoids (13). This cell 
population contained in vitro hemato/endothelial (VE-cad+CD45-Lyve1-) and 
endothelial (VE-cad+CD45-Lyve1+) activity and was different from the VE-cad+/-
CD45+ cell subset that contained both HSC and hematopoietic progenitors (HP). 
To determine the relative levels of F8 RNA production in the different E12 FL cell 
subsets, FACS sorting for hemato/endothelial cells (VE-cad+CD45-Lyve1-), 
endothelial sinusoidal progenitor cells (VE-cad +CD45-Lyve1+), leukocytes (VE-
cad+/-CD45+) and non-endothelial, non-leukocyte cells (VE-cad-CD45-) was 
performed (Figure 2A). Also F8 RNA production by foetal hepatocytes and 
enriched fraction of mesenchymal cells was assessed. Cells were FACS sorted 
based on expression of the Dlk1 hepatoblast marker (41) and exclusion of 
endothelial, blood and erythroid cells (VE-cad-CD45-Ter119-Dlk1+ as 
hepatoblasts and VE-cad-CD45-Ter119-Dlk1- as a cell subset that included 
mesenchymal cells (42, 43)(Figure 2B). Higher levels for F8 RNA expression were 
observed in VE-cad+CD45-Lyve1- hemato/endothelial progenitors and VE-
cad+CD45-Lyve1+ endothelial sinusoidal progenitor cells compared with CD45+ 
blood cells, Dlk1+ hepatoblasts or other cell types included in the VE-cad-CD45-
Ter119-Dlk1- cell population (Figure 2C). This result indicates that, similarly to 
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the adult liver (10), the main population producing F8 RNA in the FL is of 
endothelial nature. 
It is of note the relative low level of F8 RNA production of unfractionated E12 FL 
cells compared to adult liver. This is consistent with the fact that in the adult liver 
the main cellular components, endothelial cells and hepatocytes, were reported to 
produce F8 RNA (10, 44) while Ve-cad+CD45-Lyve+/- cells only represent the 
0.6±0.2% of E12 FL cells, an organ mostly composed by erythroblast at this stage. 
Further studies are required to determine if endothelial progenitors/endothelial 
cells are also the main producers of F8 RNA in the different embryonic locations.  
 
The AGM explant culture expands cells with LSEC engraftment potential 
Establishment of culture systems for differentiation/proliferation of foetal 
progenitor cells with LSEC vascular potential is of interest for therapeutic 
applications. As both hematopoietic and endothelial progenitor cell subsets can be 
involved in the efficient vascular engraftment (45, 46) and FVIII production (10), 
we reasoned that the AGM explant (AGMex) culture system, supportive of both 
hematopoietic and some types of endothelial/endothelial precursor expansion 
(47-49) could be optimal.  To test this idea, AGMex from E11 SCL-PLAP transgenic 
embryos were set up for 3 days, followed by cell suspension and  transplantation 
of 30x104 cells i.v. into busulfan treated newborn recipient mice. Cells from 
uncultured E11 AGMs were also transplanted as control. At 4 months post-
transplantation hematopoietic and liver vascular engraftment were assessed 
(scheme in Figure 3A). Hematopoietic engraftment was observed in all mice 
transplanted with cells from AGMex (8 out of 8) as determined by FACS for the 
PLAP reporter gene expression in peripheral blood (Figure 3 B, Table 2). This 
constituted a robust increment in hematopoietic engraftment frequency 
compared to controls transplanted with uncultured E11 AGM cells (8 out of 17) in 
agreement with previous reports (Table 2, Figure 3A) (15). Immuno-histological 
analysis of liver sections from chimeras showed that only animals transplanted 
with cells from AGMex presented PLAP+ donor endothelial cell engraftment in the 
liver (3 out of 8) resembling LSEC cells (Figure 3C), similar to the frequency of 
vascular chimerism obtained from E12 AGM cells (4 out of 10, not shown) (13), 
while control mice transplanted with uncultured E11 AGM cells did not present 
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donor derived vascular clusters in the liver (0 out of 8). Phenotypic analysis of 
cells from AGMex did not show an increment on VE-cad+CD45-Lyve1+/- cells 
(Figure 3D). Indeed, the frequency of VE-cad and Lyve-1 dropped drastically 
compared to CD45 cells after the explants.  Considering that culture medium 
components are not defined, we cannot exclude the possibility that down 
regulation/internalization of the VE-cad and Lyve-1 receptors might occur during 
AGM culture as described for dermal tissue explants under the influence of pro-
inflamatory signals (50). More work is needed to determine the characteristics of 
cells with LSEC engraftment potential and their relation to FL derived cells. 
Altogether this indicates that E11 AGM explant cultures promoted LSEC 
engraftment activity. 
FLex cultures have been shown unsuitable for expansion of HSC potential (15), 
but this did not exclude the possibility that they could maintain/expand LSEC 
activity. Thus FLs were cultured in similar conditions as AGMex. Cells from FLex 
were transplanted and mice were analysed at 4 months. A drastic reduction in 
hematopoietic engraftment activity was observed from FLex cells (1 out of 9) 
compared to cells from uncultured FL (5 out of 6), in agreement with results from 
other groups (15) (Figure 3A, Table 2). Also, no increment in vascular engraftment 
was obtained from FLex compared with uncultured controls as only one of the 8 
mice analysed presented PLAP+ donor derived LSECs while all FL transplanted 
mice presented vascular grafts (Figure 3C, Table 1). This indicates that FLex are 
not optimal to promote vascular or hematopoietic engraftment activity.  
 
  
DISCUSSION 
 
Different types of primary postnatal cells capable of producing FVIII have been 
used in transplantation for correction of bleeding phenotype of adult HA mice, 
including adult LSEC (5) and blood cells (10, 51), however adult LSEC can not 
engraft the liver when transplanted into busulfan conditioned new-born recipient 
mice (13).  In the same way, adult BM-derived HSCs are less efficient than FL cells 
to repopulate the adult (19) or new-born hematopoietic system (52). FL and AGM 
derived cells efficiently engraft both the hematopoietic system and LSECs when 
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transplanted in new-born individuals (13), providing simultaneously with blood 
and endothelial daughter cell types that can potentially produce FVIII upon 
engraftment. Moreover, the concurrent administration of hematopoietic and 
endothelial progenitors can be beneficial for vascular integration as it has been 
shown that hematopoietic-derived cells produce paracrine factors that promote 
neo-angiogenesis upon vascular injury in diverse tissues (45, 46), including 
promotion of LSECs proliferation in the damaged liver (53). Therefore, it is of 
interest to characterize foetal cells as potential targets for HA cell therapy in 
neonatal and young individuals, a stage when adult derived cells seem to engraft 
less robustly, if at all. The work presented here demonstrates the expression of 
FVIII in FL and AGM cells and shows that AGMex can expand cells with LSEC 
engraftment potential, providing the bases to further assess their ability to long 
term rescue FVIII production and bleeding coagulation deficiencies in new-born 
and adult HA mice. 
 In the experiments presented here a degree of correlation between levels of FL-
derived hematopoietic and vascular engraftment were not observed. This does 
not exclude the possibility that donor-derived pro-angiogenic activity could rely 
in a subset of hematopoietic cells not directly derived from HSCs or their 
descendent cells. Indeed, fetal myeloid cells have been reported to contribute to 
vessel anastomosis and remodeling during embryogenesis (54, 55). Moreover, 
previous results from our group showed that transplantation of E12 FL Ve-
Cad+CD45-Lyve+/- cells, devoid of HSC activity, resulted in long term vascular 
engraftment of recipient mice. Interestingly, Ve-Cad+CD45- Lyve+/-  chimeras, 
presented vascular clusters that also included few donor derived CD45+ cells (13). 
These results indicated that hematopoietic cells associated with the vascular 
grafts, potentially pro-angiogenic, were not derived from HSCs or their 
descendants.  Thus, a correlation of hematopoietic and vascular repopulation 
might not always occur. Incrementing the number of chimeras and performing co-
transplantation assays with different FL HSC/myeloid/macrophage cell subsets 
(54, 55) would be necessary to determine the contribution of different fetal CD45+ 
hematopoieitc cells for vascular graft formation.   
In agreement with previous results a basal level of FVIII production has been 
evidenced during mouse embryonic development (56). The progressive age raise 
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on F8 transcripts in the whole embryo correlated with an increase of F8 in 
different locations, potentially related to a general increase of angiogenesis during 
mid gestation (29, 30). The first mesodermic angioblast progenitors appear 
around day 7 (E7) of mouse development. By E8 angioblasts aggregate forming a 
simple circulatory circuit consisting of a heart, dorsal aorta, yolk sac plexus and 
sinus venosus. This circuit is remodelled by extensive endothelial cell 
proliferation and maturation, generating a complex vascular network of 
endothelial tubes including arteries, veins and lymphoid vessels that specialize in 
each organ (29).  Considering that, in the adult mice the principal EC types 
producing FVIII are LSEC and lymphoid endothelium (9), it is expected that the 
concomitant increment on embryonic LSECs (57, 58) and lymphoid vessels by 
stage E12 (59) should have an impact on FVIII expression levels.  It is of interest 
that the E12 AGM constitutes one of the main producers of FVIII, significantly 
higher than FL at the RNA and protein level. We speculate that the FVIII could be 
produced by the dorsal aorta (DA) VE-cad+CD45- endothelial cells (EC), a 
heterogeneous population constituted by structural EC, including Lyve1+ cells (13, 
60), and hemogenic endothelial cells (HEC) capable of generating HSC and 
hematopoietic progenitor cells (14). Characterization of distinctive markers and 
transcriptomic profiling for EC, HEC and HC has been a topic of intense interest, 
however the expression of FVIII has not been reported as far as we know. This 
could be because most studies related to HEC and HSC have focused on early 
embryonic stages (E10-E11) that produce much reduced levels of F8 RNA as 
shown here (Figure 1) (61, 62). It remains to be determined what types of AGM-
derived ECs produce FVIII, the relation with Lyve1+ cells and the LSEC 
engraftment ability.   
Data showing the FVIII protein secretion by human FL derived LSECs would 
support this functionality in counterpart VE-cad+CD45-Lyv1+/- mouse cells (24). 
Fomin et al have characterized the LSECs in human FL as CD14++CD45- cells 
expressing the EC markers VE-cad and CD31, molecules expressed by the murine 
cells (13). CD14++CD45- cells form part of the liver sinusoids and constitute the 
main human FL population producing F8 RNA, similar to murine VE-cad+CD45-
Lyv1+/- cells. Transplanted unfractionated human FL cells into adult uPA-NOG 
mice, immuno-deficient mice overexpressing an urokynase-type plasminogen 
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activator under albumin promoter, engrafted the hematopoietic system and LSEC.  
Importantly, engrafted mice presented levels of human derived FVIII in circulation 
similar to those found in human plasma (24). This information in combination 
with our Western blot results, supports the idea that FL derived cells can produce 
FVIII protein. Still, transplantation of FL cell subsets into HA mice remains to be 
done to determine specific/synergistic FVIII secretion by hematopoietic and LSEC 
engrafted cells and long-term amelioration of the bleeding phenotype.  
 
Culture conditions that promote long-term maintenance of LSECs for 
transplantation remain challenging as LSEC lose their characteristics in vitro (63). 
The results shown here indicate that AGMex culture constitutes an alternative to 
expand cells with LSECs engraftment potential. AGMex and derivatives were 
described more than two decades ago as a culture system capable of expanding 
different mesoderm progenitor cells, including HSCs and hematopoietic 
progenitor cells (15) and aorta-derived myogenic cells and mesoangioblast 
progenitor (47). AGM cell suspension cultures have also shown expansion of high 
proliferative potential hemangioblast (HPP-HA) precursors, endothelial 
progenitors and endothelial cells (49, 64). Here we have shown for the first time 
that AGMex can also expand cells with LSEC engraftment potential. For 
therapeutic purposes, the AGMex culture could be used in combination with FVIII 
gene transfer strategies, generally effective in 2-3 days, and provide a working 
frame to characterize molecules instrumental in the more effective derivation of 
LSEC from iPSCs (65). Advanced cell therapy approaches could promote a curative 
treatment of severe HA at early age, an inherited disease that presently, can only 
be palliatively treated.  
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FIGURE LEGENDS 
 
Figure 1. F8 expression during embryo development. (A) Quantitative PCR 
showing F8 relative expression in whole embryos at different stages. Histograms 
represent the mean±SD values from biological replicated, samples, n=3. (B) 
Quantitative PCR showing F8 RNA relative expression levels obtained at different 
developmental stages for the indicated embryonic/fetal tissues. For E12 foetal liver 
and AGM region mean ±SD values were obtained from 5 independent experiments. For 
the rest of the tissues n=3. (C) The relative levels of F8 expression in adult liver used as 
positive control are shown,  n=6.   GAPDH was used as normalization control. Statistical 
significance (P≤ 0.05 using a U-Mann-Whitney test) of the F8 levels from E12 tissues is 
indicated with asterisks. (D) (i) FVIII production by Western blot.  20 g of total protein 
from E12 foetal  tissues and HEPG2 cell line lysates and 5 g  from adult tissue were 
run on a 7.5% Tris acetate gel and blotted on NC membranes. (ii) 48 ug of total protein 
from adult liver was run.  FVIII proteins were identified with a monoclonal antibody 
against FVIII A2 domain, an HRP-labelled secondary antibody and ECL detection 
reagent. FL, full length protein (A1-A2-B-A3-C1-C2 domains); SC, single heavy chain 
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(A1-A2-B domains); HC, heavy chain (including different fragments from A1-A2-B 
domains); *, unspecific band.  
 
 
Figure 2. FVIII expression in E12 FL cell subsets. (A) FL cells were stained for 7AAD, 
VE-cad-APC (V), CD45-PE (C) and Lyve1-FITC (L). 7AAD- viable cells were gated and 
non-endothelial non-hematopoietic (V-C-), hematopoietic (V+/-C+), hemato-vascular 
progenitor (V+C-L-) and endothelial cell (V+C-L+) fractions isolated for RNA extraction. 
(B) FL cells were stained for 7AAD, VE-cad-APC (V), CD45-PE and Ter119-PE (CT) and 
DLK1-FITC (D). Gated non-hematopoietic/erythroid cells (V-CT-) (dotted gate) were 
subdivided according to Dlk1 expression into a mesenchymal enriched fraction (V-CT-
D-) and hepatoblast (V-CT-D+) for RNA extraction. Percentage of cell population is 
indicated on each quadrant in the FACS dot plots. Percentage in the histogram plot is 
referred to the dotted line sorting gate. Representative values for one experiment are 
shown. n=3 sorting experiments using the V-C-L staining strategy and n=2 for the V-C-
T-D staining strategy. (C) qPCR showing FVIII relative expression from sorted FL 
populations. The mean±SD values are represented. Values were obtained from n=3 V-
C-L sorting experiments and n=2 V-C-T-D- sorting experiments, run simultaneously in 
triplicates for qPCR, Statistical significance using a U-Mann-Whitney test was indicated 
as  p≤0.1 (*) and p≤0.01 (**). 
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Figure 3. AGMex cultures expand cells with LSEC engraftment potential. (A) 
Experimental design. The AGM region (circle) and the liver (arrow) from E11 SCL-PLAP 
transgenic embryos were dissected. Tissues were homogenized for direct 
transplantation or explanted separately onto filters supported by stainless steel mesh 
stands at the air–liquid interface. Tissues were cultured for 3 days, dissociated and cells 
transplanted into busulfan conditioned new-born recipients to determine 
hematopoietic and LSEC engraftment activity at 4 months post-transplantation. The 
frequency of hematopoietic and vascular chimerism is indicated: a)number of recipient 
mice showing donor cells in peripheral blood; b)total number of mice transplanted; 
c)number blood chimeras showing donor derived LSECs clusters in the liver; d)total 
number of animals analysed for vascular chimerism. The number of transplantation 
experiments performed for each cell type were as follows, AGM, n=5; AGMex, n=3; FL, 
n=4; FLex, n=3. (B) Analysis of AGMex cell hematopoietic engraftment in the peripheral 
blood. Representative flow cytometry analysis is shown comparing peripheral blood 
from representative WT, SCL-PLAP transgenic (TG) and AGMex chimera. Erythrocyte 
depleted peripheral blood cells were stained for the donor reporter marker PLAP and 
CD45. Mean ±SD values for peripheral blood hematopoietic engraftment are shown in 
Table 2. The SCL-PLAP reporter gene is expressed in a fraction of mature circulating 
cells (FACS-PLAP, 15±5%). Value of 5% FACS-PLAP in the chimera is equivalent to 10-
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100% total hematopoietic chimerism as estimated by semi-quantitative PCR-PLAP (see 
Material and Methods.)  (C) Top images represent liver section stained for the PLAP 
substrate NBT from the indicated representative mice. NBT positive vascular clusters 
are shown from AGMex, FL and FLex chimeras. Liver sections from 30 transplanted 
mice, including all blood chimeras were screened for detection of NBT positive vascular 
clusters and the relative vascular cluster area (v.c.a) indicated in Table 2. 
Immunofluorescence images from liver section from the indicated mice.  PLAP+ 
clusters in liver sections chimeras are formed by elongated cells lining sinusoids 
expressing the endothelial marker Isolectine B4 (IsoB4) and very low/negative levels 
of the hematopoietic marker CD45, consistent with being LSECs  (arrows). In the merge 
panels, DAPI nuclear staining is shown in grey. Inset images are set at lower 
magnification, presenting a PLAP+ cluster in the chimeras (Sup. Figure 1) (D) 
Phenotypic analysis of donor cells.  FACS analysis was performed to compare the 
frequency of V+C-L+/- cells before and after explant cultures of E11 FL and AGM cells. 
Representative dot plots and histograms are represented. Expansion of LSEC activity 
in AGMex does not correlate with an increment on V+C-L+/- frequency,  n=2. 
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Sup. Figure 1. Immunofluorescence images from liver sections from AGMex and 
FL chimeras.  Low magnification images showing the extension of representative 
vascular clusters for the indicated chimeras. Sections were stained for detection of 
donor-derived marker PLAP, the hematopoietic marker CD45, the endothelial marker 
IsoB4 and DAPI for the nuclei.  Magnified images of delimitated tissue area by white 
squares are shown in Figure 3C. 
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Sup. Figure 2. FVIII production by Western blot. 20 g of total protein from E12 
foetal  tissues and HEPG2 cell line lysates and 5 g  from adult tissue were run on a 
7.5% Tris acetate gel and blotted on NC membranes.  FVIII proteins were identified 
with a monoclonal antibody against FVIII LC domain, an HRP-labelled secondary 
antibody and ECL detection reagent. FL, full length protein (A1-A2-B-A3-C1-C2 
domains); LC, light chain (A3-C1-C2 domains). *Unspecific band. 
 
 
Table 1. Primers design for mouse F8 and GAPDH genes analysis 
 
Genes Sequences 
Amplified size 
(bp) 
Gene Bank 
Factor VIII 
5´-GGTTTTTCAGGGGAATCAGGAC-3´ 
5´-GCCTCAGAGCAATTTGGTGC-3´ 
119 NM_007977.1 
GAPDH 
5´-CATGGCCTTCCGTGTTCCTA-3´ 
5´-GCGGCACGTCAGATCCA-3´ 
55 NM_001289726 
Abbreviations: bp, base pair; GAPDH, glyceraldehyde phosphate dehydrogenase. 
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Table 2. AGM explant culture expands cells with LSECs engraftment activity 
Donor cellsa Hematopoietic chimerismb Vascular chimerismc 
Tissue nºcells x104 
(ee) 
nºPLAP+/ 
total miced 
% PLAP+ 
(range values)g 
nºPLAP+/ 
total miceh 
PLAP+ v.c.a. 
x10-3 cm2 
(range   values) 
AGM 
20-80 8/17 6.2±6 0/8 0 
(1-4)  (1.5-15.7)   
AGMex 
30 8/8e 11.6±9 3/8 0.9 –0.13- 0.04 
(2.5)  (9.5-13.4)   
FL 
25-50 5/6f 10.6±6.7 6/6 1.2±0.5 
(2-4)  (5-18)  (0.27-1.63) 
FLex 
8-100 1/9 11.4 1/8 0.14 
(2-4)     
 
Abbreviations: AGM, aorta-gonads-mesonephros; AGMex, aorta-gonads-mesonephros explant; 
FL, foetal liver; Flex, foetal liver explant; LSEC, liver sinusoidal endothelial cell; NBT, nitroblue 
tetrazolium; PCR, polymerase chain reaction; SD, standard deviation. 
 
Note: Data were obtained from mice generated from the following number of independent 
transplantation experiments: AGM, n = 5; AGMex, n = 3; FL, n = 4; FLex, n = 3; ee, embryo 
equivalent. 
aBusulfan conditioned new-born mice were i.v. transferred with the indicated number of cells from 
uncultured or 3 days explanted tissue obtained from E11 SCL-PLAP transgenic embryos. 
Transplanted mice were analysed at 4 months post-transplant for hematopoietic and vascular 
engraftment. 
bHaematopoietic chimerism was expressed as the frequency of PLAP+ leukocytes in the host 
circulation assessed by flow cytometry. 
cVascular chimerism was determined by histological NBT detection of PLAP+ donor-derived cells 
forming vascular-like clusters on liver sections and animals scored as positive when at least one 
vascular cluster was observed. The mean values of relative tissue area containing the PLAP+ 
vascular-like clusters referred to the total tissue area analysed are indicated for each group 
(vascular cluster area, v.c.a.). 
d Chimerism determined in peripheral blood by flow cytometry. The number of PLAP+ chimeras 
related to the total analysed mice is shown. 
e One AGMex chimera was only analysed by PCR-PLAP 
f Two FL chimeras were only analysed by PCR-PLAP. 
g Mean ± SD values for % PLAP+ cells in the circulation from positive mice. % PLAP from SCL-
3′Enh-PLAP transgenic animals were 15 ± 5%. 
h Positive animals presenting PLAP+ vascular clusters in liver sections stained for NBT from the 
total number of analysed mice. Analysed mice include all PLAP+ haematopoietic chimeras and 1 
FL and 7 FLex transplanted mice not presenting haematopoietic chimerism. 
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Sup. Table 1. Regression analysis of F8 RNA level increment with age.  
LOG WE Liver AGM YS Heart Head Limb Somite 
Intercept -13.22 -13.30 -16.70 -9.73 -11.35 -14.30 -14.85 -13.34 
Slope 0.44 0.40 0.82 0.045 0.31 0.57 0.57 0.42 
R2 76.16 53.52 88.48 4.19 57.38 74.11 49.15 58.94 
P-Value <10-4 <10-4 <10-4 0.231 <10-4 <10-4 0.0012 <10-4 
 
Abbreviations: AGM, aorta-gonads-mesonephros; RNA, ribonucleic acid; WE, 
whole embryo; YS, yolk sac. 
Note: To determine the statistical significance of F8 RNA levels increment with 
age, a regression analysis was performed for whole embryos (WE) and indicated 
tissues obtained from stages E8 to E12 as shown in Figure 1. The logarithm 2-ΔCt 
values for F8 RNA were used as dependent variable.  Results of the analysis 
indicate that there is a significant  (p<0.05) correlation of age and F8 RNA 
production in most samples, except for the yolk sac (YS), where the low levels for 
F8 RNA do not increment with the developmental stage. 
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EXTRA TABLE 
What is known about this topic? 
 
 Coagulation factor VIII (FVIII) is produced by endothelial and some 
hematopoietic cells in adult individuals. 
 Transplantation of adult liver sinusoidal endothelial cells (LSECs) and 
bone marrow-derived hematopoietic cells into adult FVIII deficient 
haemophilic A mice ameliorates the coagulation defect, constituting 
targets for HA cell therapeutic approaches.  
 Foetal hematopoietic and endothelial progenitor cells present an 
improved hemato and vascular engraftment potential compared to adult 
counterpart cell types, particularly in neonatal host receptors, however 
less is known about foetal liver (FL) and AGM FVIII production and LSEC 
activity generation in vitro. 
What does this paper add? 
 
 FVIII transcripts are produced in the foetal liver and AGM region, main 
hematopoietic locations during mid-gestation developmental stage. 
 FVIII transcripts are mainly produced by a FL derived cell population 
with LSEC engraftment potential in new-born receptors. 
 AGM explanted cultures increment hematopoietic and LSEC engraftment 
activity.  
 Highlights the potential foetal derived cells have for HA cell therapeutic 
approaches in young individual.   
 
 
 
 
 
